Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.


Clinical Trial Description

PRIMARY OBJECTIVE: I. For each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, fluciclovine F18 [18F-fluciclovine] PET, MR spectroscopy), to evaluate whether the biomarker can stratify patients with newly diagnosed glioblastoma (GBM) that have progressive enhancement within 12 weeks post-radiation therapy (XRT) into risk groups based on overall survival. SECONDARY OBJECTIVES: I. To evaluate whether each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, 18F-fluciclovine PET, MR spectroscopy) can predict final determination of pseudo-progression (PsP) versus (vs.) true progression on follow-up MR imaging as evaluated by a semi-automated central reading process and by institutional radiologist readings. II. To evaluate whether a prediction model that incorporates multiple biomarkers can discriminate patients with progressive enhancement within 12 weeks post-XRT into high and low risk groups for overall survival. III. To evaluate whether clinical and imaging biomarkers are predictive of overall and progression-free survival in patients who do not show progressive enhancement within 12 weeks post-XRT. EXPLORATORY OBJECTIVE: I. To determine how different methods of defining PsP vs. true progression on imaging relate to patient survival. OUTLINE: Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of standard of care (SOC) radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 intravenously (IV) and undergo PET scan within 12 weeks of SOC radiation therapy completion. After completion of study intervention, patients are followed up every 8 weeks for 1 year followed by every 12 weeks for 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06319027
Study type Interventional
Source Eastern Cooperative Oncology Group
Contact
Status Not yet recruiting
Phase Phase 2
Start date April 12, 2024
Completion date May 31, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05941234 - Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma N/A
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT06160596 - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Recruiting NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Not yet recruiting NCT04945148 - Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide Phase 2
Not yet recruiting NCT05842746 - Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma Phase 2
Not yet recruiting NCT06419946 - Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Phase 3
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Recruiting NCT06418113 - Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma Phase 1
Recruiting NCT05326334 - THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
Recruiting NCT05375318 - BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
Not yet recruiting NCT06359379 - Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Phase 2
Recruiting NCT06095375 - Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients Phase 1
Recruiting NCT05879367 - Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT05759195 - Biomolecular Analysis for Predicting Response to Regorafenib N/A
Recruiting NCT06273176 - The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)